Entries by

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

March 1, 2016 in /by

A screen of microbial-derived products using a 3D model of the human airway epithelium (bronchospheres) revealed flagellin (FLG) as a potential regulator of mucociliary structure and function. Flagellin, a TLR5-agonist, is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. Considering that mucus plugs in the airways of […]

New drug discovery company announces additional funding to tackle chronic respiratory disease

May 20, 2015 in /by

Brighton, Sussex, May 20th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing. The funds are comprised of £2m by new investor, Imperial Innovations and £0.4m increase by founding investor Epidarex, bringing the total Series-A […]

World class drug discovery team launches new company to tackle chronic respiratory disease

February 12, 2015 in /by

Brighton, Sussex, February 12th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focussed on novel therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug discovery and new target identification programs. The company will be […]